Medical experts at Berkeley County town hall warn of kratom risks, especially powerful synthetic derivatives
Get AI-powered insights, summaries, and transcripts
Subscribe
Summary
Emergency physicians and prevention specialists described kratom’s pharmacology and clinical harms, saying lab‑made derivatives like 7‑hydroxy mitragynine can be far more potent and unpredictable than the plant’s native alkaloids and can require clinical treatment similar to opioid withdrawal.
Medical and prevention experts at a Berkeley County town hall described kratom’s pharmacology, clinical harms and complications in treatment, and urged clinicians and the public to treat suspected overdoses with caution.
Dr. Kelly Young, an emergency physician at Roper Saint Francis, said kratom (Mitragyna speciosa) can have stimulant effects at low doses and opioid‑like sedative effects at higher doses because its alkaloids act on mu opioid receptors. She listed adverse effects including nausea, hepatotoxicity, seizures and, in some cases, psychotic symptoms and said there are no FDA‑approved uses for kratom.
Alan Easler, a prevention coordinator at Cornerstone, summarized environmental scans showing kratom products sold in convenience stores and vape shops and said potency can vary widely by product and by dose. He described mitragynine and the more potent derivative 7‑hydroxy mitragynine, and cited federal and journal summaries indicating that mitragynine has substantially lower receptor potency than morphine while 7‑hydroxy forms can be many times more potent; presenters emphasized that many retail 7‑hydroxy products are synthetically produced in labs to achieve commercial scale.
Clinical implications: Dr. Young recounted an ER patient whose chronic kratom and 7‑hydroxy use made standard opioid dosing less effective for acute pain. Panelists said kratom can complicate medication‑assisted treatment and sometimes requires hospital‑level care for severe withdrawal; they advised first responders and clinicians to consider naloxone in suspected overdose situations because co‑ingestants may be present and because naloxone can be lifesaving.
Quantities and testing: Presenters described extreme reported daily use in anecdotal cases (tens of grams per day), noted that one capsule is typically about 0.5 gram and that low doses are often listed as 1–5 grams while higher doses are 5–15 grams. They also said many standard toxicology panels do not test for kratom alkaloids, complicating clinical and legal confirmation of exposure.
What the scientists and clinicians asked for: clearer regulatory definitions for synthetic derivatives, improved laboratory testing availability, clinician guidance on treating kratom‑related intoxication and withdrawal, and public education about potency differences between traditional leaf use and concentrated or synthetic products.
Ending: The panel did not issue clinical guidelines; instead presenters urged clinicians and jurisdictions to expand testing panels and to share case information with public health partners so the impact can be better tracked.